Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epstein-Barr virus (EBV)-infected tumor cells are malignant or transformed cells that harbor latent or lytic EBV infection. These cells are associated with various cancers, including lymphomas, nasopharyngeal carcinoma, and gastric carcinoma. EBV infection drives oncogenesis by modifying host gene expression, inducing EMT and angiogenesis, and facilitating immune escape. The molecular profile of these cells depends on the type of latency program expressed (Latency I, II, or III), which dictates which viral genes are expressed. Detection methods include in situ hybridization for EBERs and immunohistochemistry for viral proteins. Targeting these cells therapeutically presents challenges due to the complex interplay between viral and host factors, as well as potential safety concerns related to immune modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epstein-Barr Virus-Infected Tumor Cell (EBV-Infected Tumor Cell).